News for Genetic Signatures Limited (GSS.AX)

Genetic Signatures (ASX:GSS) shares were down -1.45% to 68cps on Monday, even as the company reported a greenlight from the TGA.

Futures indicate the ASX200 will open slightly higher as a new trading week commences, driven by growing confidence that the US Federal Reserve will pause at its next rates meeting due to the increase in unemployment in the country.

Futures predict the ASX will open lower to finish the week, triggered by tech shares losing momentum on Wall Street and leading the market to also close lower.

The healthcare sector is ripe for disruption and artificial intelligence will play a big part in future drug discovery.

On Stockhead today, Taylor Collison is backing Genetic Signatures (ASX:GSS) to Outperform saying the medtech's PT could triple.

Three ASX stocks, Good Drinks (GDA), Genetic Signatures (GSS) and Zip (ZIP) have received recommendations with strong price targets.

Colossal Biosciences’ plans to bring the Tasmanian tiger and woolly mammoth back to life, but now it’s also betting on the iconic dodo.

The ASX has performed well this week, Lode Resources aced the Small Caps win and Big Gun Adani is tanking – hard – and it just keeps getting worse.

The FDA declined regulate CBD-based supplements and food citing safety reasons, but the CBD index keeps going up.

Japanese startup OUI Inc says it is on a mission to halve the world's blindness with its smartphone-based device.

Moderna’s stock price rose in late December after the company revealed that a vaccine for melanoma showed encouraging results.

The US FDA has just approved the world’s most expensive drug. CSL Behring’s hemophilia B gene therapy costs US$3.5m a dose.

ASX health stocks have fallen out of favour in 2022 with a a rotation out of growth into value sectors but could it also do with better PR?

Rise and Shine: Everything you need to know before the ASX opens

ASX 200 closes with -1.8% loss. Small cap index down 1% but up way more than 100% Norfolk Minerals - the real NFL.

Four ASX healthcare stocks have been rated as a ‘Strong Buy' by Morningstar’s consensus of brokers, making them hot tips.

There were 191 ASX IPOs in calendar year 2021, and 15 of them were biotech stocks.But in 2022 there were only 3 biotech listings.

Blood clot was top of biotech news this week after researchers revealed new discovery that could prevent it without risk of bleeding.

Winter’s nearly over and the Covid surge in Australia has slowed down dramatically. New cases are now rapidly declining.